Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of ...

Additional early research suggested that combining metformin and clemastine may promote remyelination, offering hope for ...

Most people with relapsing MS who were treated with Briumvi for six years did not have confirmed disability progression, a ...

Selma Blair’s lifelong health struggles were signs of multiple sclerosis that doctors wouldn't acknowledge until she was in ...

Blair revealed that despite experiencing symptoms since childhood, her multiple sclerosis (MS) wasn’t diagnosed until she was ...

Most relapsing MS patients on Mavenclad did not have confirmed disability progression for at least four years, new Phase 4 trial data show.

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...

With over 1 million Americans affected by multiple sclerosis (MS), we wanted to learn more about its symptoms, particularly ...

WEST PALM BEACH, Fla. -- The investigational oral Bruton's tyrosine kinase (BTK) inhibitor evobrutinib failed to distinguish itself from teriflunomide (Aubagio) in two phase III trials of relapsing ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...